Boston Scientific Corporation (BSX) |
73.505 4.515 (6.54%) 04-24 11:51 |
Open: | 73.14 |
High: | 74.39 |
Low: | 72.55 |
Volume: | 6,052,601 |
Market Cap: | 108,045(M) |
PE Ratio: | 68.7 |
Exchange: | New York Stock Exchange |
Industry: | Medical - Devices |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 86.89 |
Resistance 1: | 74.39 |
Pivot price: | 68.52 |
Support 1: | 69.70 |
Support 2: | 66.80 |
52w High: | 74.39 |
52w Low: | 48.35 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
EPS | 1.070 |
Book Value | 13.150 |
PEG Ratio | 2.44 |
Gross Profit | 0.000 |
Profit Margin (%) | 11.18 |
Operating Margin (%) | 16.56 |
Return on Assets (ttm) | 4.5 |
Return on Equity (ttm) | 8.6 |
Wed, 24 Apr 2024
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised - Zacks Investment Research
Wed, 24 Apr 2024
Here's Why Boston Scientific Corporation (BSX) Rose in Q1 - Yahoo Finance
Wed, 24 Apr 2024
Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript - Seeking Alpha
Wed, 24 Apr 2024
Boston Scientific Corp (BSX) Q1 2024 Earnings: Surpasses Analyst Revenue Forecasts and EPS Estimates - GuruFocus.com
Wed, 24 Apr 2024
Boston Scientific (BSX) Beats Expectations with $3.8 Billion in Q1 Net Sales - The Tokenist
Wed, 24 Apr 2024
2024-04-24 | NYSE:BSX | Press Release | Boston Scientific Corp - Stockhouse Publishing
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |